BACKGROUND/ OBJECTIVES: Herpes simplex virus type 2 (HSV-2) is a common infection among HIV infected people. HSV type specific serologies permit the diagnosis of previously unrecognised HSV-2 infection. While substantial psychosocial morbidity has been associated with a clinical diagnosis of genital herpes, the burden associated with a serological diagnosis of HSV-2 is unclear. This study prospectively measured the psychosocial response to a new serological HSV-2 diagnosis in patients receiving care at an urban HIV clinic. METHODS: At entry, sera were tested for HSV-1 and HSV-2 antibodies by western blot. Participants completed a 90 item psychosocial and life quality questionnaire at enrollment, and at 2 weeks, 3 months, and 6 months after receiving test results. RESULTS: Of 248 HIV infected participants, 172 (69.4%) were HSV-2 seropositive and 116 (67.4%) seropositive people did not have a previous history of genital herpes. After correction for multiple comparisons, no statistically significant differences were detected on the psychosocial and life quality scales between those who received a new HSV-2 serological diagnosis compared with those who were HSV-2 seropositive with a history of genital herpes, or those who tested HSV-2 seronegative. Additionally, no significant changes in scores were observed during follow up. CONCLUSIONS: HSV-2 was a common but often unrecognised infection in this urban HIV clinic and participants coped well with a positive HSV-2 result. Concerns about psychosocial burden should not deter serological testing for HSV-2. Given the epidemiological and clinical interaction between HSV-2 and HIV, these data support routine HSV-2 testing of HIV infected people.
BACKGROUND/ OBJECTIVES:Herpes simplex virus type 2 (HSV-2) is a common infection among HIV infected people. HSV type specific serologies permit the diagnosis of previously unrecognised HSV-2 infection. While substantial psychosocial morbidity has been associated with a clinical diagnosis of genital herpes, the burden associated with a serological diagnosis of HSV-2 is unclear. This study prospectively measured the psychosocial response to a new serological HSV-2 diagnosis in patients receiving care at an urban HIV clinic. METHODS: At entry, sera were tested for HSV-1 and HSV-2 antibodies by western blot. Participants completed a 90 item psychosocial and life quality questionnaire at enrollment, and at 2 weeks, 3 months, and 6 months after receiving test results. RESULTS: Of 248 HIV infectedparticipants, 172 (69.4%) were HSV-2 seropositive and 116 (67.4%) seropositive people did not have a previous history of genital herpes. After correction for multiple comparisons, no statistically significant differences were detected on the psychosocial and life quality scales between those who received a new HSV-2 serological diagnosis compared with those who were HSV-2 seropositive with a history of genital herpes, or those who tested HSV-2 seronegative. Additionally, no significant changes in scores were observed during follow up. CONCLUSIONS:HSV-2 was a common but often unrecognised infection in this urban HIV clinic and participants coped well with a positive HSV-2 result. Concerns about psychosocial burden should not deter serological testing for HSV-2. Given the epidemiological and clinical interaction between HSV-2 and HIV, these data support routine HSV-2 testing of HIV infected people.
Authors: G J Mertz; O Schmidt; J L Jourden; M E Guinan; M L Remington; A Fahnlander; C Winter; K K Holmes; L Corey Journal: Sex Transm Dis Date: 1985 Jan-Mar Impact factor: 2.830
Authors: A Wald; A G Langenberg; K Link; A E Izu; R Ashley; T Warren; S Tyring; J M Douglas; L Corey Journal: JAMA Date: 2001-06-27 Impact factor: 56.272
Authors: Lawrence Corey; Anna Wald; Raj Patel; Stephen L Sacks; Stephen K Tyring; Terri Warren; John M Douglas; Jorma Paavonen; R Ashley Morrow; Karl R Beutner; Leonid S Stratchounsky; Gregory Mertz; Oliver N Keene; Helen A Watson; Dereck Tait; Mauricio Vargas-Cortes Journal: N Engl J Med Date: 2004-01-01 Impact factor: 91.245
Authors: J Melville; S Sniffen; R Crosby; L Salazar; W Whittington; D Dithmer-Schreck; R DiClemente; A Wald Journal: Sex Transm Infect Date: 2003-08 Impact factor: 3.519
Authors: S L Rosenthal; G D Zimet; J S Leichliter; L R Stanberry; K H Fife; W Tu; D I Bernstein Journal: Sex Transm Infect Date: 2006-04 Impact factor: 3.519
Authors: Hayley Mark; Joy P Nanda; Alain Joffe; Jessica Roberts; Anne Rompalo; Johan Melendez; Jonathan Zenilman Journal: J Am Coll Health Date: 2008 Nov-Dec
Authors: Angela Devine; Xiuqin Xiong; Sami Lynne Gottlieb; Maeve Britto de Mello; Christopher K Fairley; Jason J Ong Journal: Health Qual Life Outcomes Date: 2022-02-16 Impact factor: 3.186